Which Swiss Companies Outsource Pharma Projects to Indian Firms? (Including Divi’s Labs Partnerships) — Complete Guide 2025

 

Switzerland is one of the world's most powerful pharma hubs, home to giants like Novartis, Roche, Lonza, and dozens of innovative biotech companies. Over the last decade, these Swiss companies have steadily increased their outsourcing partnerships with Indian pharma and CDMO players, driven by India’s strong chemistry expertise, cost advantage, and globally compliant facilities.

Among the Indian players, Divi’s Laboratories stands out as a key supplier to multiple Swiss pharma and specialty chemical companies, thanks to its dominance in APIs, intermediates, and custom synthesis.

This post gives a full, updated list of Swiss pharma companies outsourcing to India, highlighting Divi’s Labs' Swiss linkages.

---

⭐ Major Swiss Pharma Companies That Outsource to Indian Pharma

1. Novartis (Basel)

Outsourced Work:

• API intermediates

• Custom synthesis

• Discovery chemistry

• Analytical testing

• Clinical data & support

Indian partners:
Divi’s Labs, Syngene, Sai Life Sciences, Aragen, Jubilant

Novartis is one of the largest Swiss clients for Indian CDMOs across early research and manufacturing.

---

2. Roche (Basel)

Outsourcing Areas:

• Discovery biology and chemistry

• Biologics analysis

• Non-core analytical testing

• Pharmacovigilance

Indian partners:
Syngene, Aragen, selected niche biologics units

Roche focuses more on discovery and biologics outsourcing rather than large-scale API manufacturing.

---

3. Lonza (Basel)

Although Lonza is itself a global CDMO, it still outsources specific early-stage and speciality chemistry projects to India.

Outsourced Areas:

• Small-molecule intermediates

• Custom chemistry

• Analytical support

Indian partners:
Sai Life, Aragen, Divi’s Labs (for select intermediates)

Lonza collaborates with Indian partners mostly in non-core small-molecule segments.

---

🔶 Divi’s Laboratories: Swiss Business Connections

Divi’s Labs is one of India’s most respected CDMOs, known for:

• High-purity APIs

• Large-scale intermediates

• Custom synthesis

• Advanced chemistry for innovators

• Long-term supply agreements

Divi’s has a strong and growing business with Switzerland.

Swiss Companies Linked With Divi’s Labs

1. Novartis

   • Long-standing supplier relationship

   • Supplies intermediates, specialty APIs, and custom chemistry

   • Novartis relies on Divi’s for stable, high-scale manufacturing

2. Lonza (Indirect supply chain interactions)

   • Divi’s supplies advanced intermediates used in Lonza’s global supply network

   • Mainly for small-molecule programs

3. Roche (select program-level chemistry support through the supply chain)

   • Niche intermediates in earlier stages

   • Not public but present via subcontracting layers

4. Smaller Swiss companies

   • Bachem (peptide intermediates and fine chemicals)

   • Siegfried (certain intermediates; indirect procurement)

   • Acino (specialty raw material sourcing for formulations)

Divi’s Labs benefits from the fact that Switzerland is a global center for high-value chemistry, making it a perfect match for Divi’s custom synthesis strength.

---

4. Vifor Pharma (CSL Vifor)

Outsourced Areas:

• API intermediates

• FDF manufacturing collaborations

• Stability batches

Indian partners:
Aurobindo, Zydus, Divi’s (intermediates), MSN

---

5. Acino Pharma (Swiss HQ)

What They Outsource:

• Oral solid formulations

• Complex generics

• Specialty APIs

Indian partners:
Aurobindo, Dr. Reddy’s, Strides, and Divi’s (select intermediate sourcing)

---

6. Siegfried Holding AG

A large CDMO, but occasionally outsources upstream work to India.

Outsourced Areas:

• Raw material support

• High-volume intermediates

• Technology transfer studies

Indian partners:
Hikal, Divi’s Labs, Piramal, Granules

---

7. Swiss Specialty & Biotech Firms

Many smaller Swiss companies outsource for cost-efficient development.

Swiss Company	Outsourced Focus	Indian Partners (including Divi’s)
Bachem	Peptide intermediates	Divi’s Labs, small peptide CDMOs
OM Pharma	Fermentation/biotech support	Syngene, Aragen
Polichem	Dermatology formulations	Indian FDF firms
Ferring (Swiss HQ)	API intermediates	Divi’s Labs, Hikal

---

🌍 Why Swiss Companies Prefer India

1. High Chemistry Strength

India’s process chemistry expertise is unmatched.

2. Strong Regulatory Reputation

India has the highest number of USFDA-approved plants outside the U.S.

3. Scalability

Indian CDMOs handle both micro-scale and multi-ton manufacturing.

4. Cost Benefits

Up to 40–60% lower cost for R&D and manufacturing.

5. Complete End-to-End Ecosystem

India offers:

• Discovery

• Development

• Scale-up

• API

• Formulation

• Packaging

Swiss companies love this one-stop model.

---

🔮 Outlook 2025–26: What’s Next?

• Swiss outsourcing to India expected to grow 12–15% CAGR.

• Rising demand for API security increases India’s role.

• Divi’s Labs set to benefit from Swiss demand for high-purity intermediates and custom synthesis.

• New U.S.–Swiss trade adjustments may encourage Switzerland to expand sourcing from India to keep costs optimized.

---

📌 Conclusion

Swiss pharma companies rely heavily on India for cost-efficient, reliable, and high-quality outsourcing. Whether it is global giants like Novartis and Roche or specialty firms like Bachem and Acino, India’s CDMO ecosystem plays a central role in their supply chains.

Companies like Divi’s Labs, Syngene, Sai Life Sciences, Aragen, and Piramal have become essential strategic partners for Switzerland’s pharmaceutical ecosystem.

As complexity in drug development increases, this India–Switzerland collaboration will only grow stronger over the coming years.